TRANSMEDICS GROUP INC (TMDX)
US89377M1099 - Common Stock
Taking everything into account, TMDX scores 5 out of 10 in our fundamental rating. TMDX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in each of the past 5 years.
In the past 5 years TMDX always reported negative operating cash flow.
1.2 Ratios
TMDX has a Return On Assets of 4.15%. This is in the better half of the industry: TMDX outperforms 79.68% of its industry peers.
TMDX has a Return On Equity of 15.55%. This is amongst the best in the industry. TMDX outperforms 90.91% of its industry peers.
With a decent Return On Invested Capital value of 3.43%, TMDX is doing good in the industry, outperforming 73.80% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 15.55% | ||
| ROIC | 3.43% |
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TMDX has a Profit Margin of 8.14%. This is in the better half of the industry: TMDX outperforms 79.68% of its industry peers.
TMDX has a Operating Margin of 7.84%. This is in the better half of the industry: TMDX outperforms 75.94% of its industry peers.
TMDX's Gross Margin of 59.34% is in line compared to the rest of the industry. TMDX outperforms 57.75% of its industry peers.
In the last couple of years the Gross Margin of TMDX has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.84% | ||
| PM (TTM) | 8.14% | ||
| GM | 59.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
TMDX has more shares outstanding than it did 1 year ago.
TMDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TMDX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.61 indicates that TMDX is not a great score, but indicates only limited risk for bankruptcy at the moment.
TMDX's Altman-Z score of 2.61 is fine compared to the rest of the industry. TMDX outperforms 63.64% of its industry peers.
TMDX has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
TMDX has a worse Debt to Equity ratio (2.42) than 85.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.61 |
ROIC/WACC0.41
WACC8.45%
2.3 Liquidity
TMDX has a Current Ratio of 8.20. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TMDX (8.20) is better than 89.84% of its industry peers.
TMDX has a Quick Ratio of 7.33. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.33, TMDX belongs to the best of the industry, outperforming 90.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.2 | ||
| Quick Ratio | 7.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 185.45% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 109.09%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.35% yearly.
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.38%
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Sales Q2Q%63.72%
3.2 Future
The Earnings Per Share is expected to grow by 53.77% on average over the next years. This is a very strong growth
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.46% yearly.
EPS Next Y228.76%
EPS Next 2Y98.04%
EPS Next 3Y71.76%
EPS Next 5Y53.77%
Revenue Next Year88.35%
Revenue Next 2Y52.58%
Revenue Next 3Y40.98%
Revenue Next 5Y33.46%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 65.64, the valuation of TMDX can be described as expensive.
66.31% of the companies in the same industry are more expensive than TMDX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.20, TMDX is valued quite expensively.
A Price/Forward Earnings ratio of 41.69 indicates a quite expensive valuation of TMDX.
70.59% of the companies in the same industry are more expensive than TMDX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of TMDX to the average of the S&P500 Index (23.73), we can say TMDX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.64 | ||
| Fwd PE | 41.69 |
4.2 Price Multiples
TMDX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 66.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 45.77 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 71.76% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y98.04%
EPS Next 3Y71.76%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TRANSMEDICS GROUP INC
NASDAQ:TMDX (12/20/2024, 8:00:01 PM)
After market: 62 +0.3 (+0.49%)61.7
+1.17 (+1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners108.14%
Inst Owner Change8.93%
Ins Owners3.15%
Ins Owner Change2.59%
Market Cap2.07B
Analysts82.5
Price Target127.5 (106.65%)
Short Float %28.59%
Short Ratio4.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.77%
Min EPS beat(2)-59.86%
Max EPS beat(2)63.4%
EPS beat(4)3
Avg EPS beat(4)312.78%
Min EPS beat(4)-59.86%
Max EPS beat(4)957.84%
EPS beat(8)6
Avg EPS beat(8)131.87%
EPS beat(12)8
Avg EPS beat(12)89.63%
EPS beat(16)10
Avg EPS beat(16)63.89%
Revenue beat(2)1
Avg Revenue beat(2)2.97%
Min Revenue beat(2)-7.28%
Max Revenue beat(2)13.23%
Revenue beat(4)3
Avg Revenue beat(4)8.86%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)16.17%
Revenue beat(8)7
Avg Revenue beat(8)15.29%
Revenue beat(12)11
Avg Revenue beat(12)22.22%
Revenue beat(16)13
Avg Revenue beat(16)17.29%
PT rev (1m)-31.69%
PT rev (3m)-30.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)100%
EPS NY rev (1m)-8.97%
EPS NY rev (3m)-23.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.54%
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-3.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.64 | ||
| Fwd PE | 41.69 | ||
| P/S | 5.16 | ||
| P/FCF | N/A | ||
| P/OCF | 55.3 | ||
| P/B | 9.86 | ||
| P/tB | 10.56 | ||
| EV/EBITDA | 45.77 |
EPS(TTM)0.94
EY1.52%
EPS(NY)1.48
Fwd EY2.4%
FCF(TTM)-3.59
FCFYN/A
OCF(TTM)1.12
OCFY1.81%
SpS11.95
BVpS6.26
TBVpS5.85
PEG (NY)0.29
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 15.55% | ||
| ROCE | 4.34% | ||
| ROIC | 3.43% | ||
| ROICexc | 6.28% | ||
| ROICexgc | 6.51% | ||
| OM | 7.84% | ||
| PM (TTM) | 8.14% | ||
| GM | 59.34% | ||
| FCFM | N/A |
ROA(3y)-16.47%
ROA(5y)-20.03%
ROE(3y)-34.23%
ROE(5y)-38.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.58%
GM growth 5Y7.7%
F-Score6
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.42 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 10.35 | ||
| Cap/Depr | 893.16% | ||
| Cap/Sales | 39.38% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 76.19% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.2 | ||
| Quick Ratio | 7.33 | ||
| Altman-Z | 2.61 |
F-Score6
WACC8.45%
ROIC/WACC0.41
Cap/Depr(3y)797.55%
Cap/Depr(5y)487.14%
Cap/Sales(3y)29.07%
Cap/Sales(5y)17.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)185.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.38%
EPS Next Y228.76%
EPS Next 2Y98.04%
EPS Next 3Y71.76%
EPS Next 5Y53.77%
Revenue 1Y (TTM)109.09%
Revenue growth 3Y111.22%
Revenue growth 5Y79.35%
Sales Q2Q%63.72%
Revenue Next Year88.35%
Revenue Next 2Y52.58%
Revenue Next 3Y40.98%
Revenue Next 5Y33.46%
EBIT growth 1Y187.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.19%
EBIT Next 3Y84.72%
EBIT Next 5Y64.1%
FCF growth 1Y-98.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.33%
OCF growth 3YN/A
OCF growth 5YN/A